Evidence map›Paper›PMID 37693048›Full record

ArticleBioengineering & translational medicine2023

Secure reversal of immune evasion from refractory NSCLC and highly contagious CoV-2 mutants by using 3D-engineered multifunctional biologics.

Yanna Zhang, Qian Li, Nanxi Liu, Jianchuan Hu, Xiaojuan Lin, Meijuan Huang, Yuquan Wei, Xiaorong Qi, Xiancheng Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yanna ZhangDepartment of Blood Transfusion, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu Sichuan China.
Qian LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.
Nanxi LiuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.ORCID https://orcid.org/0000-0001-5036-0280
Jianchuan HuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.
Xiaojuan LinDepartment of Gynecology & Obstetrics, West China Second Hospital Sichuan University Chengdu China.
Meijuan HuangDivision of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu China.
Yuquan WeiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.
Xiaorong QiDepartment of Gynecology & Obstetrics, West China Second Hospital Sichuan University Chengdu China.
Xiancheng ChenDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.
Sichuan University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an imperative choice to develop a secure feasible strategy to address evasion dynamics of refractory tumors and SARS-CoV-2-variants, while stem cell-based protocol may be more reliable as its unique ability for resetting multifunctional immunity to address progressive tumor and the constantly-evolving virus. In this study, spheroid-embryonoid stem cells from mature somatic cells were engineered as multifunctional biologics (3D-E/BSC) and inoculated in senile rhesus to identify secure potential against immune-evasion from viral-variants. Meanwhile, a cohort of eligible patients with stage IV NSCLC were approved for phase I clinical trials. Subsequently, long-lasting security and efficacy were validated by primate and clinical trials (

Indexed as

evasion dynamicshighly transmissible SARS‐Cov‐2 variantsmultifunctional E/BSCrefractory NSCLCvoided‐microenvironment reset

Identifiers

PMID37693048
PMCPMC10487317
OpenAlexW4381848157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.